Mylan Inc. plans to ship generic gabapentin capsules, indicated for the treatment of a painful complication of shingles.


Mylan, gabapentin capsules, Neurontin, Pfizer, Neurontin generic, shingles, Matrix Laboratories, Mylan Pharmaceuticals, seizures






































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Mylan approved for Neurontin generic

February 28th, 2011

PITTSBURGH – Mylan Inc. plans to ship generic gabapentin capsules, indicated for the treatment of a painful complication of shingles.

The company said Monday that its Matrix Laboratories Ltd. subsidiary has received final approval from the Food and Drug Administration for its abbreviated new drug application (ANDA) for gabapentin capsules USP in dosages of 100 mg, 300 mg and 400 mg.

The product, a generic version of Pfizer's Neurontin capsules, is being launched immediately by Mylan Pharmaceuticals Inc.

Gabapentin capsules had U.S. sales of about $300 million last year, according to IMS Health data reported by Mylan.

An anti-epileptic medication, gabapentin capsules may also be used for nerve pain from herpes zoster (shingles) infection (postherpetic neuralgia).

Advertisement